FDA Panel Backs AstraZeneca Gout Drug Amid Dosage Concerns
A U.S. Food and Drug Administration advisory panel on Friday recommended the agency approve AstraZeneca's gout medication, lesinurad, after considering a report by FDA scientists that suggested higher doses of the drug...To view the full article, register now.
Already a subscriber? Click here to view full article